Shengting Medical

Shengting Medical, established in 2013 by Professor Hongcang Gu from Harvard University & MIT Broad Institute and Mr. Yongjun Tu, Chairman of Tianyu Co., Ltd. (300702), is a "National High-tech Enterprise." Over the past decade, Shengting Medical has focused on innovative research in medical genomics and the application of precision medicine. In the fields of oncology and infectious diseases, it has developed two core technologies: ultra-low-input DNA/RNA co-sequencing for tumors and nanopore-targeted pathogen diagnostic technology. The company has applied for 29 invention patents, obtained more than 40 software copyrights, and received authoritative certification from the College of American Pathologists (CAP). Shengting Medical is dedicated to the research and application of medical genomics, supported by a multidisciplinary R&D team composed of experts from around the world. In the field of oncology, it has developed products and services covering the entire cancer cycle, including early screening, medication guidance, prognosis monitoring, and new drug development services for tumors based on patented targeted capture and methylation sequencing core technologies. To date, Shengting Medical has provided precision medical testing services to over 100,000 cancer patients.